To Get Full Access :
Joenja is the first FDA‑approved oral selective PI3Kδ inhibitor for activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS). It is administered to patients aged 12 years and older, targeting the underlying immune signaling defect in APDS to address both immunodeficiency and immune dysregulation.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
